Which oral tablet is safer: amitriptyline, nortriptyline, or duloxetine?

Duloxetine is the safest option among these three medications

For most patients, duloxetine represents the safest choice, followed by nortriptyline, with amitriptyline being the least safe option. This recommendation is based on cardiovascular safety profiles, anticholinergic burden, and real-world adverse event data.

Safety Profile Comparison

Cardiovascular Safety

Duloxetine has the most favorable cardiac safety profile. The medication does not produce clinically important electrocardiographic changes or blood pressure alterations 1. In contrast, tricyclic antidepressants (TCAs) carry significant cardiac toxicity concerns. Guidelines specifically recommend prescribing TCAs with caution in patients with ischemic cardiac disease or ventricular conduction abnormalities, limiting dosages to less than 100 mg/day when possible, and obtaining screening electrocardiograms for patients older than 40 years 1.

Among the TCAs, nortriptyline is safer than amitriptyline because it has lower anticholinergic properties and reduced cardiotoxic effects 2, 3. A large retrospective study demonstrated increased risk of sudden cardiac death with TCA doses exceeding 100 mg/day 3.

Anticholinergic Effects and Falls Risk

Amitriptyline carries the highest burden of anticholinergic side effects including sedation, dry mouth, urinary hesitancy, and constipation 2. These effects are particularly problematic in older adults.

A 2023 real-world study of 195,207 older adults (≥65 years) found that compared to nortriptyline as the reference medication, all other antidepressants showed significantly higher risk for falls, fractures, and syncope 4. Specifically:

• Duloxetine had 25% higher risk for falls (aHR 1.25) and 30% higher risk for fractures (aHR 1.30) compared to nortriptyline
• Amitriptyline had 20% higher risk for falls (aHR 1.20) but similar fracture risk to nortriptyline
• For syncope, duloxetine showed similar risk to nortriptyline, while amitriptyline also showed equivalent risk

This evidence suggests nortriptyline has the lowest risk for falls and fractures in older adults, which is a critical safety consideration given that falls can lead to serious morbidity and mortality.

Tolerability and Common Adverse Effects

Duloxetine's most common adverse effect is nausea, which can be mitigated by starting at 30 mg once daily for one week before increasing to 60 mg 1. Other side effects include somnolence, dizziness, constipation, dry mouth, and decreased appetite 1.

Nortriptyline causes less sedation and fewer anticholinergic effects than amitriptyline 2, 5, making it better tolerated overall among the TCAs.

Amitriptyline has the most problematic side effect profile with pronounced anticholinergic effects. In a palliative care study, dry mouth occurred in 55% of amitriptyline patients versus 24% with duloxetine 6.

Clinical Decision Algorithm

For patients under 65 years without cardiac disease:

• First choice: Duloxetine (best cardiac safety, no ECG monitoring required)
• Second choice: Nortriptyline (if duloxetine not tolerated or contraindicated)
• Avoid: Amitriptyline (highest anticholinergic burden)

For patients ≥65 years or with fall risk:

• First choice: Nortriptyline (lowest fall/fracture risk in this population 4)
• Second choice: Duloxetine (acceptable if nortriptyline not tolerated)
• Avoid: Amitriptyline (highest anticholinergic effects, increased fall risk)

For patients with cardiac disease or conduction abnormalities:

• Only choice: Duloxetine (no cardiac conduction effects 1)
• Avoid: Both TCAs (require ECG monitoring, dose limitations, cardiac toxicity risk 1)

For patients with hepatic impairment:

• Avoid: Duloxetine (risk of hepatic failure 7)
• Consider: Nortriptyline with caution

Important Caveats

Monitoring Requirements

• TCAs (amitriptyline, nortriptyline): ECG screening recommended for patients >40 years; monitor for cardiac conduction abnormalities 1
• Duloxetine: Monitor height, weight, pulse, and blood pressure; watch for hepatic dysfunction 7, 8

Drug Interactions

Duloxetine has significant CYP2D6 inhibition, increasing desipramine levels 3-fold 8. Use caution with other CYP2D6 substrates.

All three medications carry risk of serotonin syndrome when combined with MAOIs or other serotonergic drugs 8.

Pregnancy and Lactation

Duloxetine is present in breast milk at <1% of maternal dose 8. Safety data for TCAs in pregnancy is limited. All require careful risk-benefit assessment.

Discontinuation

Duloxetine and other SNRIs require slow taper to avoid withdrawal syndrome 1, 7. TCAs should also be tapered gradually 5.

The evidence consistently demonstrates that duloxetine offers the best overall safety profile for most patients, particularly regarding cardiovascular safety. However, in older adults specifically concerned about falls and fractures, nortriptyline emerges as the safest option based on high-quality real-world evidence 4. Amitriptyline should generally be avoided unless the other two options are contraindicated or ineffective, given its inferior safety profile across multiple domains.